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Summary 
Transient transfection of human embryonic kidney cells (HEK 293) enables the rapid and 
affordable lab-scale production of recombinant proteins. In this chapter protocols for the 
expression and purification of both secreted and intracellular proteins using transient expression 
in HEK 293 cells are described. 
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1 Introduction 
High quality, pure proteins are important reagents for a wide variety of applications such as 
biochemical assays, protein-based therapeutics and protein crystallography.  E. coli remains the 
most commonly used expression host for producing recombinant proteins for research purposes, 
for example structural studies, due to its ease of use and relatively low cost.  However, 
production of recombinant proteins in high yield from E. coli can be challenging due to low 
expression levels and poor solubility.  This is particularly the case for mammalian proteins.  
Although expression of many human intracellular proteins has been tried in E. coli, about 65 % 
are either not expressed or expressed insolubly (1).  These problems may be overcome by using 
mammalian cells for protein production as these express the necessary chaperones for correct 
folding and contain the machinery for adding post-translational modifications (PTMs).  
Mammalian cells also contain small molecules and cofactors which may be required for protein 
expression or complex formation. 
Two mammalian cell lines are routinely used for the production of recombinant proteins, 
Chinese hamster ovary (CHO) and human embryonic kidney (HEK 293) cells.  Of these, HEK 
293 cells have become the mammalian cell line of choice for lab-scale protein production due to 
their ease of culture and high transfection efficiency (2).  A useful variant of HEK cells is the 
293T cell line which expresses the SV40 large T antigen.  Expression vectors containing the 
SV40 origin of replication are episomally amplified within the 293T cells, which increases the 
plasmid copy number per cell and can lead to higher levels of transient expression (3).  A further 
variant of the HEK cell line is the FreeStyle™ HEK 293F cell line (Life Technologies, UK) in 
which the HEK 293 cells are adapted to suspension growth in FreeStyle™ 293 expression 
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medium. The medium is designed to support high-density growth and has the advantage of 
allowing transfection without the need to change medium. 
The use of the inexpensive cationic polymer, polyethylenimine (4-5) as the DNA condensing 
reagent has meant that large scale transient transfection of HEK 293 cells has become 
economically feasible and is routinely used for the production of secreted and cell surface 
glycoproteins (reviewed by Aricescu and Owens (6)). 
In contrast to their use with secreted proteins, mammalian cells have not been used routinely for 
the production of intracellular proteins due to the relatively low levels of expression compared 
with insect or bacterial systems.  However, by using highly selective purification methods, e.g. 
FLAG® tag (7) or Halo® tag (8), it is possible to achieve useful yields of intracellular proteins.  
Again, transient expression in HEK 293 cells offers a way of rapidly assessing the protein yield 
and quality.  Subsequent production of stable cell lines, typically by co-selection, may be 
required to sustain and improve the production levels of a particular product. 
In this chapter, protocols for the production of both secreted and intracellular proteins by 
transient transfection of HEK 293 cells are described.  The methods are exemplified by reference 
to the production of the secreted protein, human serum amyloid P component (SAP) and the 
intracellular proteins, human brain specific protein kinase C isoform protein kinase M zeta 
(PKMζ) and human histone deacetylase 3 (HDAC3) in complex with its activation domain from 
the SMRT co-repressor (SMRT-DAD). 
SAP is a plasma glycoprotein (9) which participates in the innate human immune system but also 
plays a role in the molecular pathology of diseases such as amyloidosis and amyloid associated 
diseases such as Alzheimer’s and Type II diabetes (10).  SAP is of increasing clinical relevance 
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as radio-labelled SAP is used for identifying sites of amyloid deposition (11), whilst drug 
development programs attempting to deplete serum levels (for treatment of amyloidosis) and also 
administer protein (for treatment of fibrosis) are currently underway (12-13).  SAP contains an 
N-glycan and a disulphide bridge and is representative of proteins with these modifications.   
PKMζ is a neuron-specific isoform of atypical protein kinase C (aPKC) that lacks the normal N-
terminal regulatory region and therefore comprises just a kinase catalytic domain (14).  In vivo 
phosphorylation of PKMζ by PDK1 converts PKMζ into a conformation with high constitutive 
activity (15).  Although there is controversy as to the extent and nature of its role, PKMζ has 
been implicated in both memory (16) and pain (17).  PKMζ contains 5 cysteines (with the 
potential for disulphide bridge formation) and is activated via phosphorylation. 
HDAC3 is a class I histone deacetylase (HDAC) that is involved in transcriptional regulation 
(18). Like the other class I HDACs, HDAC3 requires recruitment to its cognate co-repressor 
protein (SMRT) to have full enzymatic activity (19). HDACs are important therapeutic targets 
for the treatment of cancer (20), and are involved in other diseases such as Alzheimer’s and HIV 
(21-22). HDAC3 and its activation domain from the SMRT co-repressor (SMRT-DAD) do not 
interact when expressed in bacterial cells but require expression in higher eukaryotes to form a 
complex.  The HDAC3:SMRT-DAD complex is phosphorylated in the C-terminal region of 
HDAC3 and also acetylated (as determined by mass spectrometry).  The structure of the 
HDAC3:SMRT-DAD complex revealed the presence of an Ins(1,4,5,6)P4 molecule at the 
interface between HDAC3 and SMRT which is required for complex formation and activation 
(23). 
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To show the benefit of using mammalian rather than bacterial cells to express human proteins, 
SAP and PKMζ were tested for expression in both E. coli and HEK 293 cells (24-26).  In Figure 
1 it can be seen that SAP in a vector containing a signal sequence is expressed and secreted using 
HEK cells (Figure 1, lanes 1 and 2), but not in E. coli (lanes 3 and 4).  Without the signal 
sequence, some SAP is accumulated in the cells using HEK cell expression (lane 6), but there is 
no expression in E. coli (lanes 7 and 8).  The band in lane 6 migrates lower than those in lanes 1 
and 2 as no post-translational modification has taken place.  For PKMζ, expression can be seen 
in the cells and in the soluble extraction for both HEK cells and E. coli (lanes 9 to 12), however 
expression levels are higher using HEK cells (lanes 9 and 10). 
2 Materials 
2.1 Protein expression using HEK 293T cells 
1. HEK 293T cells (ATCC no. CRL-1573 – LGC Standards, UK). 
2. Dulbecco’s modified Eagles medium (DMEM) (Life Technologies, UK). 
3. Foetal calf serum (FCS) (Biosera, France). 
4. Non-essential amino acids (1:100) (Life Technologies, UK). 
5. L-Glutamine (Sigma-Aldrich, UK). 
6. T175 tissue culture flask (Greiner Bio-One, UK). 
7. Plasmid DNA:  The gene of interest needs to be contained in a vector compatible 
with mammalian expression systems (See Note 1). 
8. Polyethyleneimine (PEI) (25 kDa branched PEI – Sigma-Aldrich, UK).  Prepare a 
100 mg/ml stock solution in water before diluting to 1 mg/ml.  Neutralise the 
solution with HCl, filter sterilise and store at -20°C in aliquots. 
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9. Kifunensine (Toronto Research Chemicals, Canada). 
10. Expanded surface roller bottles (Greiner Bio-One, UK). 
11. PBS:  0.01 M phosphate buffer, 0.0027 M potassium chloride, 0.137 M sodium 
chloride, pH 7.4 (tablets from Sigma-Aldrich, UK). 
2.2 Protein expression using HEK 293F cells 
1. FreeStyle™ HEK 293F cells (Life Technologies, UK). 
2. Gibco® FreeStyle™ 293 expression medium (Life Technologies, UK). 
3. 250 ml Erlenmeyer flask with vent cap (Corning, UK). 
4. Vent cap roller bottle (Corning, UK). 
5. Plasmid DNA:  The gene of interest needs to be contained in a vector compatible 
with mammalian expression systems (See Note 1). 
6. Polyethyleneimine (PEI) (25 kDa branched PEI – Sigma-Aldrich, UK).  Prepare a 
0.5 mg/ml stock solution in water. Neutralise the solution with HCl, filter sterilise 
and store at -20°C in aliquots. 
7. Kifunensine (Toronto Research Chemicals, Canada). 
8. Dulbecco’s phosphate buffered saline (Sigma-Aldrich, UK). 
2.3 Purification of secreted proteins using a His6 tag 
1. Äkta purification system such as Äkta Xpress (GE Healthcare Life Sciences, UK). 
2. HiLoad 16/600 Superdex S75 or S200 (GE Healthcare Life Sciences, UK). 
3. Gel Filtration Buffer:  20 mM Tris-HCl, 200 mM NaCl, pH 8.0. 
4. Nickel Wash Buffer:  50 mM Tris-HCl, 500 mM NaCl, 30 mM imidazole, pH 8.0. 
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5. Nickel Elution Buffer:  50 mM Tris-HCl, 500 mM NaCl, 500 mM imidazole, pH 
8.0. 
6. 96 deep well plate (Greiner Bio-One, UK). 
7. 5 ml HisTrap FF column (GE Healthcare Life Sciences, UK). 
2.4 Purification of intracellular proteins using a 3xFLAG® tag  
1. Flag Lysis Buffer: 100 mM potassium acetate, 50 mM Tris base pH 7.5, 5 % (v/v) 
glycerol, 0.3 % Triton X-100, Roche complete protease inhibitor tablet (Roche, 
UK). 
2. Flag Wash Buffer 1: 100 mM potassium acetate, 50 mM Tris base pH 7.5, 5 % 
(v/v) glycerol, 0.3 % Triton X-100. 
3. Flag Wash Buffer 2: 300 mM potassium acetate, 50 mM Tris base pH 7.5, 5 % 
(v/v) glycerol. 
4. Flag Cleavage Buffer: 50 mM potassium acetate, 50 mM Tris base pH 7.5, 5 % 
(v/v) glycerol, 0.5 mM tris (2-carboxyethyl) phosphine (TCEP). 
5. Anti-FLAG® M2 resin (Sigma-Aldrich, UK). 
6. Flag Equilibration Buffer: 100 mM potassium acetate, 50 mM Tris base pH 7.5. 
7. His-TEV (Tobacco etch virus) protease solution.  A plasmid for the expression of 
His-tagged TEV protease using E. coli is available from Addgene, USA 
(www.addgene.org). 
8. Amicon Ultra Centrifugal filter (Millipore, UK). 
9. HiLoad 10/300 Superdex S75 or S200 (GE Healthcare Life Sciences, UK). 
10. Gel Filtration Buffer:  50 mM potassium acetate, 25 mM Tris base pH 7.5, 0.5 
mM TCEP. 
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3 Methods 
3.1 Protein expression using attached HEK 293T cells 
Depending on the scale of expression required and the equipment available, methods for 
both T175 static flasks and roller bottles are described below. 
3.1.1 Medium scale using T175 flasks 
1. All cell manipulations are carried out in a Class 2 laminar flow hood. 
2. Seed HEK 293T cells at 7.5 x 105 cells/ml in 5 ml so that the cells are ~80 % 
confluent after 24 hours.  Make up to 45 ml with DMEM containing 2 % FCS, 1 x 
non-essential amino acids and 1 mM glutamine. 
3. Incubate the cells at 37°C in a 5 % CO2/95 % air atmosphere for 24 hours. 
4. Mix 87.5 µl plasmid DNA (See Note 2) with 2.6 ml of DMEM supplemented with 
1 x non-essential amino acids and 1 mM glutamine. 
5. In a separate vessel, mix 154 µl 1 mg/ml PEI with 2.6 ml of DMEM containing 1 
x non-essential amino acids and 1 mM glutamine.  Add this to the DNA cocktail 
made in step 4 and mix thoroughly. 
6. Incubate at room temperature for 10 minutes (See Note 3). 
7. Remove the supernatant from the T175 flask of confluent HEK 293T cells. 
8. Add the transfection cocktail made in steps 4-6 to the cells. 
9. Top up the flask with 40 ml of DMEM containing 2 % FCS, 1 x non-essential 
amino acids and 1 mM glutamine. 
10. If control of glycosylation is required, add 45 µl of 1 mg/ml kifunensine to the 
T175 flask (See Note 4). 
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11. Incubate the flask at 37°C in a 5 % CO2/95 % air atmosphere for 3 days at which 
point the phenol red pH indicator in the DMEM should start to change colour to 
orange. 
12. To harvest a secreted protein:  Collect the supernatant (which contains the 
protein), centrifuge at 6,000g for 15 minutes to remove any detached cells, and 
filter through a 0.22 µm bottle top filter before storing at 4°C. 
13. To harvest an intracellular protein:  Remove the supernatant and discard before 
freezing the T175 flask at -80°C. 
3.1.2 Large scale using roller bottles 
1. Each roller bottle contains 250 ml of culture so 4 roller bottles are needed per litre 
of culture. 
2. Seed HEK 293T cells at around 7.5 x 105 cells/ml in 20 ml into each roller bottle 
(See Note 5) and add 250 ml DMEM containing 2 % FCS, 1 x non-essential 
amino acids and 1 mM glutamine. 
3. Incubate the roller bottle at 37°C for 4 days with the bottle rotating at 30 rpm (See 
Note 6).  After this time, the cells should be ~80 % confluent. 
4. Remove the spent media from the roller bottle and replace with 200 ml DMEM 
containing 2 % FCS, 1 x non-essential amino acids and 1 mM glutamine.  Return 
the roller bottle to the incubator. 
5. Mix 0.5 mg of plasmid DNA (See Note 2) with 25 ml of DMEM with 1 x non-
essential amino acids and 1 mM glutamine. 
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6. In a separate vessel, mix 875 µl of 1 mg/ml PEI with 25 ml of DMEM containing 
1 x essential amino acids and 1 mM glutamine.  Add this to the DNA cocktail 
from step 5 and mix thoroughly. 
7. Incubate at room temperature for 10 minutes (See Note 3). 
8. Add the transfection cocktail made in steps 5-7 to the roller bottle. 
9. Top up the flask with 200 ml of DMEM containing 2 % FCS, 1 x non-essential 
amino acids and 1 mM glutamine. 
10. If control of glycosylation is required, add 0.25 ml of 1 mg/ml kifunensine to the 
roller bottle (See Note 4). 
11. Incubate the roller bottle at 37°C with the bottle rotating at 30 rpm (See Note 6) 
for 3-6 days.  The point of harvest is determined by the phenol red pH indicator in 
the DMEM starting to change colour to orange. 
12. To harvest a secreted protein:  Collect the supernatant (which contains the 
protein), centrifuge at 6,000g for 15 minutes to remove any detached cells, and 
filter through a 0.22 µm bottle top filter before storing at 4°C. 
13. To harvest an intracellular protein:  Remove the supernatant and discard.  Detach 
cells from the roller bottle by shaking and harvest by centrifugation at 6,000g for 
15 minutes.  Wash the roller bottle in 125 ml PBS and use this solution to 
resuspend the cell pellet, thus washing the cells to remove any remaining media.   
Centrifuge for a further 15 minutes at 6,000g and freeze the resulting pellet at -
80°C. 
3.2 Protein expression using suspension HEK 293F cells 
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Depending on the scale of expression required and the equipment available, methods for 
both 250 ml Erlenmeyer flasks and roller bottles are described below.  For co-
transfections of two or more plasmids, the total amount of DNA used must be as 
indicated in the protocols below.  
3.2.1 Medium scale using 250 ml flasks 
1. 250 ml flasks will support between 30 and 100 ml culture. For transfection 
volumes greater than 30 ml the protocol can be scaled accordingly.  
2. All cell manipulations are carried out in a Class 2 laminar flow hood. 
3. Seed cells at 3.5 x 105 cells/ml in to a 250 ml flask with a final volume of 30 ml. 
4. Incubate flask at 37°C in a 5 % CO2/95 % air atmosphere with the bottle rotating 
at 120 rpm for 3 days until the cells reach a density of > 2 x 106 cells/ml. 
5. Dilute 30 g plasmid DNA (total) (See Note 2) in 3 ml PBS and vortex briefly. 
6. Add 120 L of 0.5 mg/ml PEI to the diluted DNA and vortex briefly. 
7. Incubate at room temperature for 20 minutes. 
8. Add the PBS, DNA and PEI cocktail to 27 ml cells at 1 x 106 cells/ml final 
concentration. 
9. If control of glycosylation is required, add 30 μl of 1 mg/ml kifunensine to the 
flask (See Note 4). 
10. Incubate flask at 37°C in a 5 % CO2/95 % air atmosphere for 48 hours. 
11. To harvest protein: centrifuge cells at 6,000g for 5 minutes.  For intracellular 
protein retain cells and store at -80°C and for secreted protein retain supernatant 
and filter through a 0.22 µm bottle top filter before storing at 4°C. 
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3.2.2 Large scale using roller bottles 
1. Each roller bottle contains 300 ml of culture so 4 roller bottles are needed for 1.2 l 
of culture. Roller bottles will support a minimum volume of 150 ml and a 
maximum volume of 300 ml, for volumes less than 300 ml the protocol can be 
scaled accordingly.  
2. Seed cells at 3.5 x 105 cells/ml in to a roller bottle with a final volume of 300 ml. 
3. Incubate the roller bottle at 37°C in a 5 % CO2/95 % air atmosphere with the 
vertically orientated bottle shaking at 120 rpm for 3 days until the cells reach a 
density of  > 2 x 106 cells/ml. 
4. Dilute 300 g plasmid DNA (total) (See Note 2) in 30 ml PBS and vortex briefly. 
5. Add 1.2 ml of 0.5 mg/ml PEI to the diluted DNA and vortex briefly. 
6. Incubate at room temperature for 20 minutes. 
7. Add the PBS, DNA and PEI cocktail to 270 ml cells at 1 x 106 cells/ml final 
concentration.  
8. If control of glycosylation is required, add 0.3 ml of 1 mg/ml kifunensine to each 
roller bottle (See Note 4). 
9. Incubate the roller bottle at 37°C in a 5 % CO2/95 % air atmosphere for 48 hrs. 
10. To harvest protein: centrifuge cells at 6,000g for 5 minutes.  For intracellular 
protein retain cells and store at -80°C and for secreted protein retain supernatant 
and filter through a 0.22 µm bottle top filter before storing at 4°C. 
3.3 Purification of secreted proteins using a His6 tag 
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This protocol describes an automated method for purification of secreted proteins from 
large volumes of media using an Äkta Xpress system (GE Healthcare Life Sciences, UK).  
However, the initial immobilised metal affinity chromatography (IMAC) purification step 
(described in section 3.3.2) can be disconnected from the size exclusion chromatography 
step and automated using other Äkta purification systems. 
3.3.1 Automated protocol using the Äkta Xpress 
1. Equilibrate either a HiLoad 16/600 Superdex S75 or S200 column with Gel 
Filtration Buffer (See Note 7). 
2. Insert buffer lines A1 and A2 into Nickel Wash Buffer and manually wash the 
pumps to fill the lines with buffer. 
3. Insert buffer line A3 into Nickel Elution Buffer.  Place a large empty bottle or 
flask (this needs to be larger than the sample volume) on outlet line F3 and a 96 
deep well plate in the fraction collector. 
4. Insert a pre-charged 5 ml HisTrap FF column into column position 1 of the Äkta 
Xpress. 
5.  Carefully remove line A2 from the Nickel Wash Buffer and insert into the flask 
containing the filtered protein-containing media. 
6. Run the glycoprotein purification programme transcribed in Nettleship et al.(27) 
(See Note 8). 
7. This programme will complete an automated IMAC purification followed by 
further purification by size exclusion chromatography giving protein with over 95 
% purity (See Figure 2). 
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3.3.2 Description of IMAC purification for use with other systems 
1. 50 ml of media is loaded through a 5 ml HisTrap FF column at 8 ml/min followed 
by 10 ml of Nickel Wash Buffer. 
2. Step 1 is then repeated until all the media has been loaded through the column.  
This load/wash loop reduces the impact of IMAC incompatible components in the 
media as well as addressing pressure problems due to the viscosity of the 
mammalian culture medium particularly if it contains FCS. 
3. The column is then washed with 50 ml (10 x column volume) of Nickel Wash 
Buffer before elution of the protein with 25 ml (5 x column volume) Nickel 
Elution Buffer collecting 2 ml fractions. 
4. The product can then be further purified using size exclusion chromatography. 
3.4 Purification of intracellular protein using a 3xFLAG® tag 
The protocol below describes a method of purification using the 3xFLAG® tag from a 1.2 l 
transfection.  This can be scaled appropriately for larger scale expression. This protocol, 
including the buffers stated, was developed for the purification of 3xFLAG®-HDAC3:SMRT-
DAD complex (See Note 9).  The method given is manual; however various stages of the process 
may be automated using Äkta purification systems.  After the initial Anti-FLAG® purification, a 
size exclusion column is used to further purify the protein (including removing the TEV 
protease). 
3.4.1 Initial Anti-FLAG® purification 
1. For a 1.2 l scale up, defrost the cell pellet into ~ 30 ml Flag Lysis Buffer.  
2. Lyse the cells by sonication using 5 cycles of 30 sec on/30 sec off. 
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3. Remove the cell debris by centrifugation at 30,000g for 30 min at 4°C. 
4. Meanwhile, equilibrate 1 ml of packed Anti-FLAG® M2 resin by washing three 
times with FLAG® Equilibration Buffer. 
5. Incubate the supernatant from step 3 with the Anti- FLAG® M2 resin in a 50 ml 
tube at 4°C for 1 hour.  
6. Centrifuge at 1000g for 5 min at 4°C.  Discard the supernatant and transfer the 
resin to a 15 ml tube.  Wash the resin three times with Flag Wash Buffer 1, then 
three times with Flag Wash Buffer 2, then three times with Flag Cleavage Buffer.  
7. After last wash add 10 ml Flag Cleavage Buffer to the resin along with a1:100 
mg\ml dilution of His-TEV protease (See Note 10). Incubate overnight at 4°C. 
8. Analyse the samples by SDS-PAGE.  At this stage this fraction will contain the 
His-TEV protease as well as the purified protein of interest with the 3xFLAG® 
tag cleaved.  The protein of interest is over 95 % pure discounting the protease 
(See Figures 3 and 4). 
9. Before further purification, concentrate the protein to 0.5 ml using an 
appropriately sized Amicon Ultra Centrifugal filter (See Note 11) (Millipore, 
UK).  
3.4.2 Further purification by size exclusion chromatography 
1. Based on the molecular weight of the protein of interest and the His-TEV 
protease, select either a HiLoad Superdex 10/300 S75 or S200 column (See Note 
7). 
2. Equilibrate the size exclusion column in Gel Filtration Buffer. 
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3. Inject the fractions containing the protein of interest onto the column using a 
volume lower than 0.5 ml.  Larger injection volumes can lead to a loss in 
resolution. 
4. Analyse fractions collected by SDS-PAGE to assess separation of the protein of 
interest from the TEV protease.  The protein of interest is now at sufficient purity 
(> 99 %) for crystallization and structure determination (23) (See Figure 4). 
4 Notes 
1. Many vectors are available commercially for expression in mammalian cells.  In 
the case of SAP, this was cloned into pOPINTTG which is based on pTT (5) and 
uses the signal sequence from RTPTμ (28) and adds a C-terminal His6-tag to the 
protein.  The vector used for the expression of PKMζ and HDAC3 is based on 
pcDNA3 (Invitrogen, UK) and attaches an N-terminal His10-3xFLAG® -TEV 
cleavage site tag onto the protein. 
2. DNA for transfection needs to have an A260/A280 ratio of greater than 1.8.  This 
can be obtained using standard commercial kits such as the PureLink HiPure 
Plasmid Megaprep kit from Life Technologies, UK. 
3. Incubating for longer than 10 minutes can result in loss of transfection efficiency. 
4. Kifunensine is an α-mannosidase I inhibitor which results in the secreted product 
containing only glycans of the form Man9GlcNAc2 which can be trimmed to one 
GlcNAc residue using endoglycosidase H (Man = mannose, GlcNAc = N-acetyl 
glucosamine).  This is used to create homogeneous glycans in order to aid 
crystallogenesis (29). 
5. One fully confluent T175 flask of attached cells is used per roller bottle. 
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6. Suitable roller incubators can be purchased from Wheaton Science products, NJ, 
USA. 
7. The Superdex S75 column resolves proteins in the 3 to 70 kDa molecular weight 
range and the Superdex S200 column in the 10 to 600 kDa range. 
8. The full method for the glycoprotein purification programme is written out in 
Nettleship et al. (27) and can be copied into the Method Editor section of the 
Unicorn™ software. 
9. Depending on the 3xFLAG®-tagged protein being purified, the buffer system can 
be altered for optimal protein stability.  For example, the manufacturer 
recommends 50 mM Tris-HCl, 150 mM NaCl, pH 7.4 (Sigma Aldrich, UK). 
10. Depending on the format of the vector, other proteases such as rhinovirus 3C 
protease or enterokinase can be used.  In addition, the protein may be eluted from 
the column with its tag intact using the 3xFLAG® peptide (Sigma Aldrich, UK) 
or a low pH buffer such as glycine-HCl, pH 3.5. 
11. When selecting the Amicon Ultra Centrifugal filter to be used, one should select 
the molecular weight cut off (MWCO) based on half the molecular weight of the 
protein of interest.  This is because the MWCO is calculated using a globular 
protein model whereas the protein of interest may not be globular. 
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Figure legends 
Figure 1:  Anti-His Western blot showing expression of SAP and PKMζ using HEK 293T cells 
and E. coli.  Lanes 1 to 4 show expression of SAP using a signal sequence with lane 1 showing 
secreted product from HEK cells; lane 2, the HEK whole cell extract; lane 3, secreted product 
from E. coli; and lane 4, E. coli whole cell extract.  In a similar way, lanes 5 to 8 show 
expression of SAP without the signal sequence.  Lanes 9 to 12 show expression of PKMζ with 
lane 9 showing whole cell extract from HEKs; lane 10, soluble extract from HEK cells; lane 11, 
E. coli whole cell extract; and lane 12, E. coli soluble protein extract.  (For information about the 
vectors used, see Note 1). 
Figure 2:  Example showing the purification of SAP which gave 6 mg from 1 L of media 
produced via the roller bottle protocol.  (a) Size exclusion chromatography trace and (b) SDS-
PAGE analysis of the size exclusion fractions. 
Figure 3:  SDS-PAGE showing the purification of PKMζ from a 30 ml HEK 293F experiment 
using Anti-FLAG® chromatography.  Two constructs of PKMζ were purified with lane 1 
showing TEV-cleaved protein from a construct using amino acids 184 to 592 and lane 2, amino 
acids 231 to 592. 
Figure 4:  (a) SDS-PAGE showing the purification of HDAC3:SMRT-DAD complex using Anti-
FLAG® resin. Lane 1 shows proteins bound to the FLAG® resin. Lane 2 shows the Anti-
FLAG® resin after elution of the protein with TEV protease, and Lane 3 shows soluble proteins 
in the supernatant post elution. (b) Size exclusion chromatography trace (Superdex 200 column) 
and (c) SDS-PAGE analysis of the size exclusion fractions.  
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